FUTURA MEDICAL plc Annual Report 09 01
Highlights
l Significant progress across our product pipeline putting the Company on track to have
two revenue generating products on the market in the foreseeable future
l CSD500 – Dossier submission expected later this month for CE mark approval, clearing the
way for commercial launch
l PET500 – Successfully reformulated to be marketed on an OTC basis in the USA without
further clinical or regulatory work subject to a commercial agreement being concluded
l TPR100 – Evaluation agreement signed in July 2009 with major pharmaceutical company,
and agreement subsequently extended to end of June 2010 whilst commercial terms are
being negotiated
l Reduced net loss of £1.39 million (2008: Net loss of £1.93 million)
l Increased cash resources of £1.79 million at 31 December 2009 (31 December 2008:
£0.78 million), following successful equity fundraisings
Company Overview
01 Highlights
02 Futura at a Glance
03 Product Pipeline
04 Chairman´s and Chief Executive´s Joint Review
09 Directors´ Report: Financial Review
12 Directors´ Report: Business Review
16 Directors´ Report: Corporate Governance
22 Directors´ Report: Remuneration Report
27 Directors´ Report: Statement of Responsibilities
Contents
28 Independent Auditor´s Report
30 Group Statement of Comprehensive Income
31 Group Statement of Changes in Equity
32 Group Statement of Financial Position
33 Group Statement of Cash Flows
34 Notes to the Group Financial Statements
53 Parent Company Balance Sheet
54 Notes to the Parent Company Financial Statements
56 Company Information
